findmyKOL
Clinical trialNCT06638502RecruitingPhase 1/PHASE2Interventional

Safety of HRX215 in Patients After Minor and Major Liver Resection

SponsorHepaRegeniX GmbHEnrollment80Colorectal Carcinoma Liver MetastasesLiver Resection
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The goal of this clinical trial is to learn if HRX215 is safe, tolerable and active in adults who have undergone liver resection due to colorectal carcinoma metastases. The objectives are: 1. to learn about the safety and tolerability of HRX215 2. to learn about how the body absorbs, distributes, and gets rid of HRX215. 3. to learn about clinical activity of HRX215 Researchers will compare HRX215 to a placebo (a look-alike substance that contains no drug) to investigate safety, tolerability and clinical activity in participants taking HRX215.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

France
  • Centre Hospitalier Régional Universitaire de Lille (chru) Hôpital Claude Huriez

    Lille, France

    Stephanie Truant, MD, PhD
    Recruiting
  • Hôpital Paul-Brousse - Centre Hepato-Biliaire (chb)

    Villejuif, France

    Recruiting
Germany
  • Univ. Tuebingen - Universitaetsklinik Fuer Allgemeine, Viszeral- Und Transplantationschirurgie

    Tübingen, Germany

    Recruiting
Israel
  • Rabin Medical Center

    Petah Tikva, Israel

    Eran Sadot, M, PhD, Professor
    Recruiting
  • Sheba Medical Center

    Ramat Gan, Israel

    Niv Pencovich, MD, PhD, Professor
    Recruiting
  • Tel-Aviv Sourasky Mc

    Tel Aviv, Israel

    Active, not recruiting
Spain
  • Hospital Universitario la Paz

    Madrid, Spain

    Recruiting
  • South Texas Accelerated Research Therapeutics Madrid - Ciocc - Universitario Sanchinarro

    Madrid, Spain

    Riccardo Caruso, MD, PhD
    Recruiting
  • Consorci Hospital General Universitari de València

    Valencia, Spain

    Recruiting
United States
  • Johns Hopkins Hospital

    Baltimore, Maryland, United States

    Recruiting
  • Mayo Clinic

    Rochester, Minnesota, United States

    Patrick Starlinger, M.D Ph.D.
    Recruiting
  • Cleveland Clinic

    Cleveland, Ohio, United States

    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

HRX215 capsulesPlacebo
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
6 May 2025
Primary completion
31 Jul 2027
Completion
31 Dec 2027
Last update posted
12 Aug 2026
Registered enrollment
80
Registry id
NCT06638502
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.